French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"

Launched by UNIVERSITY HOSPITAL, TOURS · Aug 10, 2023

Keywords

ClinConnect Summary

The MATRIX trial is a research study looking into a group of rare but serious kidney diseases known as thrombotic microangiopathies (TMAs). These conditions affect how blood flows in small blood vessels and can lead to problems like kidney injury and low blood cell counts. The study aims to better understand the causes, best treatment options, and outcomes for patients with TMAs by collecting detailed information from over 20 medical centers across France over a period of more than ten years.

To be eligible for the trial, participants must be adults aged 18 or older who have had a kidney biopsy due to kidney problems between 2009 and July 2022. They should also show specific signs of TMA, such as low blood cell counts or certain findings from their kidney biopsy. Importantly, patients who have had a kidney transplant are not eligible. Those who participate can expect thorough evaluations and follow-ups to help researchers learn more about these complex conditions and improve care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult patients 18 years of age or older
• • 2. Who have undergone renal biopsy of the native kidney for impaired renal function between 2009 and July 2022.
• • 3. Presence of classically defined systemic MAT (most of the following parameters: elevated LDH, decreased haptoglobin, schizocytes, thrombocytopenia and anemia) AND/OR presence of arteriolar or glomerular renal MAT as indicated by the pathologist (including endothelial turgor, mesangiolysis, double contours, presence of thrombi, fibrinoid necrosis of the arterial wall).
• Exclusion Criteria:
• • 1. Kidney transplantation